Creating organoids from head and neck cancer tumors to test new treatments
Establishment of Squamous Cell Organoids of the Head and Neck to Assess Their Response to Innovative Therapies
This study is trying to create mini versions of head and neck cancer tumors from patients' samples to see how they respond to new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Francois Baclesse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Caen and 1 other locations) |
| Trial ID | NCT04261192 on ClinicalTrials.gov |
What this trial studies
This study focuses on developing organoid cultures from squamous cell carcinoma tumors of the head and neck to evaluate their response to innovative therapies. By utilizing tumor and blood samples from patients undergoing surgery, the research aims to create models that closely resemble the original tumors. These organoids can potentially predict treatment responses and guide therapeutic decisions, bridging the gap between traditional cell lines and patient-derived xenografts. The study seeks to enhance our understanding of tumor progression and treatment efficacy in head and neck cancers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 with untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx classified as T3Nx or T4Nx or T2N+.
Not a fit: Patients with a history of other malignancies or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for patients with head and neck cancer.
How similar studies have performed: Other studies have shown success using organoids for predicting treatment responses in various cancers, indicating a promising approach for this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age; * Patient with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, classified T3Nx or T4Nx or T2N +, not previously treated; * Patient to be treated by surgery; * Patient affiliated to a social security scheme; * No opposition to participate in the study Exclusion Criteria: * Pregnant woman ; * Persons deprived of their liberty or under guardianship (including curatorship); * History of malignant pathology preceding inclusion (apart from basal cell carcinomas of the skin and carcinomas in situ of the cervix treated surgically) or concomitant at inclusion (synchronous tumor)
Where this trial is running
Caen and 1 other locations
- Centre François Baclesse — Caen, France (Recruiting)
- CHU de Caen — Caen, France (Recruiting)
Study contacts
- Study coordinator: Vianney BASTIT, MD
- Email: bastit-v@chu-caen.fr
- Phone: + 33 2 31 06 54 37
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.